Author Archives: admin


Stem Cell Clinic > Articles by: admin

Promethera Biosciences Presents Updated Clinical Results at AASLD 2019 for World’s First Stem Cell Therapy Trial using HepaStem in Acute-on-Chronic…

By Stem Cell Treatment

MONT-SAINT-GUIBERT, Belgium--(BUSINESS WIRE)--Promethera Biosciences SA, a global innovator in cell-based medicines and liver diseases, published updated clinical data from the ongoing phase 2a study (HEP101) of its lead product candidate HepaStem in patients with Acute-on-Chronic Liver Failure (ACLF) or acute decompensation (AD) at high risk of developing ACLF. The data were presented in an oral presentation at the Annual Meeting of the American Association for Study of Liver Diseases (AASLD) on November 10, 2019, in Boston, by Prometheras principal investigator Prof. F. Nevens, KULeuven, Belgium. The data set confirmed earlier findings presented at The International Liver Congress - ILC 2019 in April.

Currently, liver transplant is the only rescue treatment for patients suffering from ACLF and to a lesser degree for patients with acute decompensation of the liver (AD). There are no other existing therapies that can rescue the end-stage-liver failure. Promethera is developing HepaStem as an alternative to transplant; it consists of liver derived stem cells that are obtained from ethically donated healthy human organs and expanded in GMP culture conditions. These liver derived signaling stem cells migrate through the blood stream to reach the liver, where they support the tissue regeneration via their potent secretome.

In the trial HEP101, HepaStem has been intravenously infused in single or repeated injections in multiple ascending doses in patients to assess the tolerability and the safety profile of the treatment. The trial which recruited a total of 24 patients, including 16 patients with ACLF and 8 patients with AD has met its primary endpoint.

With one or two repeated doses up to 1.2 million cells per kilogram of body weight, no adverse events related to HepaStem occurred and no clinically significant changes were shown in platelet count, fibrinogen levels, and coagulation factors following HepaStem infusion. The demonstrated safety of two infusions of 1.2 million cells per kilogram of body weight provide solid guidance for conducting the subsequent trials. In addition to the positive safety profile, the study has shown trends in efficacy with improvement in three indicators of liver disease severity; Model for End Stage Liver Disease score (MELD), Child-Pugh score and bilirubin levels, 28 days and three months after treatment initiation. Promethera plans to demonstrate the efficacy of HepaStem at 1.0 million cells per kilogram of body weight in ACLF with a large multicentric double blind placebo-controlled trial (HEP102). The study HEP102 is expected to start end 2019.

We continue to pioneer the use of liver stem cells for the treatment of severe liver diseases and the updated status from the worlds first clinical trial evaluating a cell-based therapy in ACLF gives us confidence about the safety aspects and the broad therapeutic potential of our therapy, said Etienne Sokal, M.D., Ph.D., Prometheras Group Chief Medical Officer. As a potential first tangible alternative to organ transplantation for an ever-growing patient population, HepaStem will advance into a larger efficacy trial in ACLF focusing on a reduced need for transplantation and a decreased mortality.

Prof. Nevens added, With the data set having evolved since we last presented results at this years ILC Congress, the Phase 2a trial provides a strong rationale for further clinical evaluation of the therapeutic concept and has provided a safe dosing regimen which will guide future studies.

About Promethera Biosciences

Promethera Biosciences is a global innovator in liver therapeutics whose mission is to bring life-saving treatments to reduce the need for liver transplantation. Our lead clinical program, derived from our patented cell technology platform HepaStem, is designed to benefit from its immune-modulatory and anti-fibrotic properties. In addition to our cell-based pipeline we develop antibody technologies, such as the antiTNF-R1 antibody Atrosimab, to complement and diversify our therapeutic options. We are a team of international experts operating out of facilities in Mont-Saint-Guibert, Belgium, Durham, NC, USA, Tokyo, Japan and Basel, Switzerland.

Promethera, HepaStem, H2stem, are all registered trademarks of the PROMETHERA group.

Read the original here:
Promethera Biosciences Presents Updated Clinical Results at AASLD 2019 for World's First Stem Cell Therapy Trial using HepaStem in Acute-on-Chronic...

Triple-Drug Induction Therapy Yields Sustained Responses in Multiple Myeloma – Hematology Advisor

By Stem Cell Treatment

According to results from a study published in Blood, the 3-drug combination of bortezomib, lenalidomide, and dexamethasone (VRD) as induction therapy prior to autologous stem cell transplant (ASCT) is highly effective at achieving and maintaining high-quality responses in patients with multiple myeloma (MM).

The findings came from the ongoing, open label, randomized, phase 3 PETHEMA/GEM2012 trial (ClinicalTrials.gov Identifier: NCT01916252), which was designed to compare transplant conditioning regimens (intravenous busulfan plus melphalan vs melphalan alone) in 458 patients who received VRD induction and consolidation for newly diagnosed, symptomatic MM.

The researchers focused on a secondary end point, depth of response (complete response [CR] and measurable residual disease [MRD]) throughout induction, ASCT, and consolidation, and evaluated safety during induction. Patients, who were 65 years or younger, were administered 6 cycles of VRD, with each 28-day cycle consisting of lenalidomide given from day 1 to 21; subcutaneous bortezomib given on days 1, 4, 8, and 11; and dexamethasone given on days 1 to 4 and 9 to 12.

After 6 induction cycles, the CR rate was 33.4% and undetectable MRD rates were 28.8% and 47.4% at median thresholds of 3 x 10-6 and 3 x 10-4, respectively. Over time, responses deepened; in patients who had started cycle 6, the rates of very good partial response or better were 55.6% by cycle 3, 63.8% by cycle 4, 68.3% by cycle 5, and 70.4% after induction. Similarly, the rates of undetectable MRD at a threshold of 3 x 10-6 increased from 28.8% after induction to 42.1% after transplant and 45.2% after consolidation.

During induction, neutropenia (12.9%) and infection (9.2%) were the most common grade 3 or higher treatment-emergent adverse events. The rate of grade 2 or higher peripheral neuropathy was 17.0% (grade 3, 3.7%; grade 4, 0.2%). Treatment was disctonued in 14 patients (3.1%), and 9 patients (2.0%) died due to treatment-emergent adverse events.

Disclosures: Some authors have declared affiliations with the pharmaceutical industry. Please refer to the original study for a full list of disclosures.

Reference

1. Rosiol L, Oriol A, Rios R, et al. Bortezomib, lenalidomide, and dexamethasone as induction therapy prior to autologous transplant in multiple myeloma [published online, October 17, 2019]. Blood. doi:10.1182/blood.2019000241

Read the original here:
Triple-Drug Induction Therapy Yields Sustained Responses in Multiple Myeloma - Hematology Advisor

Global cell therapy market is expected to grow with a healthy CAGR over the forecast period from 2019-2025 – Yahoo Finance

By Stem Cell Treatment

The report on the global cell therapy market provides qualitative and quantitative analysis for the period from 2017 to 2025. The report predicts the global cell therapy market to grow with a healthy CAGR over the forecast period from 2019-2025.

New York, Nov. 11, 2019 (GLOBE NEWSWIRE) -- Reportlinker.com announces the release of the report "Cell Therapy Market: Global Industry Analysis, Trends, Market Size, and Forecasts up to 2025" - https://www.reportlinker.com/p05796546/?utm_source=GNW The study on cell therapy market covers the analysis of the leading geographies such as North America, Europe, Asia-Pacific, and RoW for the period of 2017 to 2025.

The report on cell therapy market is a comprehensive study and presentation of drivers, restraints, opportunities, demand factors, market size, forecasts, and trends in the global cell therapy market over the period of 2017 to 2025. Moreover, the report is a collective presentation of primary and secondary research findings.

Porters five forces model in the report provides insights into the competitive rivalry, supplier and buyer positions in the market and opportunities for the new entrants in the global cell therapy market over the period of 2017 to 2025. Further, IGR- Growth Matrix gave in the report brings an insight into the investment areas that existing or new market players can consider.

Report Findings1) Drivers Increasing incidences of cancer across the globe Growing aging patient population Rise in cell therapy transplantations2) Restraints The high cost of transplantation treatment Stringent regulatory policies3) Opportunities Automation in cell therapy

Research Methodology

A) Primary ResearchOur primary research involves extensive interviews and analysis of the opinions provided by the primary respondents. The primary research starts with identifying and approaching the primary respondents, the primary respondents are approached include1. Key Opinion Leaders associated with Infinium Global Research2. Internal and External subject matter experts3. Professionals and participants from the industry

Our primary research respondents typically include1. Executives working with leading companies in the market under review2. Product/brand/marketing managers3. CXO level executives4. Regional/zonal/ country managers5. Vice President level executives.

B) Secondary ResearchSecondary research involves extensive exploring through the secondary sources of information available in both the public domain and paid sources. At Infinium Global Research, each research study is based on over 500 hours of secondary research accompanied by primary research. The information obtained through the secondary sources is validated through the crosscheck on various data sources.

The secondary sources of the data typically include1. Company reports and publications2. Government/institutional publications3. Trade and associations journals4. Databases such as WTO, OECD, World Bank, and among others.5. Websites and publications by research agencies

Segment CoveredThe global cell therapy market is segmented on the basis of cell type, therapy type, application, and end-users.

The Global Cell Therapy Market by Cell Type Stem Cell Differentiated Cell

The Global Cell Therapy Market by Therapy Type Allogenic Therapies Autologous Therapies

The Global Cell Therapy Market by Application Autoimmune Diseases Oncology Dermatology Muscoskeletal Therapies Other Applications

The Global Cell Therapy Market by End-Users Hospitals and Clinics Biotechnology and Pharmaceutical Companies Research Institutes

Company Profiles NuVasive, Inc Kolon TissueGene, Inc. JCR Pharmaceuticals Co., Ltd. Osiris Therapeutics, Inc. Stemedica Cell Technologies, Inc. MEDIPOST Celgene Corporation ANTEROGEN.CO., LTD Vericel Corporation

What does this report deliver?1. Comprehensive analysis of the global as well as regional markets of the cell therapy market.2. Complete coverage of all the segments in the cell therapy market to analyze the trends, developments in the global market and forecast of market size up to 2025.3. Comprehensive analysis of the companies operating in the global cell therapy market. The company profile includes analysis of product portfolio, revenue, SWOT analysis and latest developments of the company.4. IGR- Growth Matrix presents an analysis of the product segments and geographies that market players should focus to invest, consolidate, expand and/or diversify.Read the full report: https://www.reportlinker.com/p05796546/?utm_source=GNW

About ReportlinkerReportLinker is an award-winning market research solution. Reportlinker finds and organizes the latest industry data so you get all the market research you need - instantly, in one place.

__________________________

Story continues

Clare: clare@reportlinker.comUS: (339)-368-6001Intl: +1 339-368-6001

Go here to read the rest:
Global cell therapy market is expected to grow with a healthy CAGR over the forecast period from 2019-2025 - Yahoo Finance

Takeda, Anderson Cancer Center team up for cell therapy – BSA bureau

By Stem Cell Medical Center

Takeda and Anderson Cancer Center announce cooperation to accelerate the development of clinical stage, out-of-the-box CAR NK cell therapy platform

University of Texas MD Anderson Cancer Center(The University of Texas MD Anderson Cancer Center)and Takeda Pharmaceutical Company Limited (Takeda Pharmaceutical hasannounced an exclusive licensing agreement and research agreement to develop cord blood-derived chimeric antigen receptors for "arming" IL-15 for the treatment of B-cell malignancies and other cancers Chimeric Antigen Receptor-directed Natural Killer (CAR NK) cell therapy.

Under the agreement, Takeda will receive access to the CAR NK platform of the Anderson Cancer Center and the exclusive rights to develop and commercialize up to four projects, including a CD19-targeted CAR NK cell therapy and a B-cell maturation. The antigen (BCMA) is the target of CAR NK cell therapy.The Takeda and Anderson Cancer Center will conduct a research collaboration to further develop the above CAR NK project.

Katy Rezvani, MD, Ph.D.,Professor ofStem Cell Transplantation and Cell Therapyat theAnderson Cancer Center,said: "Our vision is to improve existing treatments by developing armored CAR NK, which can be administered in outpatient settings. Out of the box, more patients can get effective, fast and least toxic treatment. Takeda's expertise in hematological malignancies and the commitment to develop next-generation cell therapies make it an ideal partner for our team. Promote CAR NK cell therapy for patients with therapeutic needs."

New ways to deliver out of the box ready to use CAR in outpatient facilitiesallogeneic Anderson Cancer Center platform CAR NK NK cells isolated from umbilical cord blood, the fight against certain cancers expressing CAR targets after processing.CAR NK cells are modified by retroviral vectors to deliver genes and enhance their efficacy against specific tumors.CD19 CAR increases the specificity of these cells against B cell malignancies, while the immune cytokine IL-15 enhances the proliferation and survival of CAR NK cells in vivo.

Existing CAR T cell therapy drugs use patient-generated genetically modified T cells, and the preparation process takes several weeks. In contrast, CAR NK cells are designed to be prepared from non-relative donor sources and stored in an out-of-the-box manner. So that treatment can be implemented faster.

CD19 CAR NK cell therapy is expected to be administered in an outpatient setting.In an ongoing phase 1/2a clinical study, patients with relapsed refractory B-cell malignancies who received CD19 CAR NK cell therapy did not see severe cytokine release syndrome (CRS) observed in existing CAR-T treatments. ) or neurotoxicity.

Anderson Cancer Center to develop CAR NK platform led by Dr. Rezvani, and withadoptive cell therapy platform,Chronic Lymphocytic Leukemia Moon ShotandB-the Cell Lymphoma Moon Shotfurther support of the project were the hospitalMoon Shots Programof In part, the project is a collaborative effort to rapidly develop scientific discoveries into meaningful clinical advances that can save patients' lives.

Takeda: CAR accelerate the development of next-generation multiple platformsAndy Plump Takeda, president of R & D, MD, Ph.D., said: "Anderson Cancer Center CAR NK cell therapy platform represents a potential cure for the drug, which is what we are to CD19 CAR NK Established as a leader in the treatment of drug candidates for cancer in the field. We must work flexibly and purposefully, so we plan to start the pivotal study of CD19 CAR NK in 2021."

In addition to CAR NK cell therapy, Takeda and its partners are investigating ways to improve the safety, efficacy, and accessibility of first-generation CAR T cell therapies, includinggamma delta CAR T,induced pluripotent stem cell-derived CAR T,with solid tumors as targets of CAR Tandother next-generation methods.Takeda plans to the end of fiscal year 2020 to promote the five kinds of tumor cell therapy to clinical stage.The platform is being developed through collaboration with partners and the use of Takeda's expertise in transforming cell therapy engines that provide bioengineering, chemistry, manufacturing and control (CMC), clinical and transformation functions in a single location to overcome cell therapy drugs. Numerous manufacturing challenges in development.

Takeda is responsible for the development, manufacture and commercialization of the CAR NK products produced by the agreement.The Anderson Cancer Center will receive upfront payments and be eligible to receive royalties for development and commercialization milestones for each target and for any CAR NK product net sales.

The Anderson Cancer Center and Takeda will continue to conduct research on other targets and the CAR NK platform under the direction of a joint research committee.The Anderson Cancer Center will deploy aninstitutional conflict of interest management and monitoring programfor the study.

More here:
Takeda, Anderson Cancer Center team up for cell therapy - BSA bureau

Takeda and MD Anderson Announce Collaboration to Accelerate the Development of Clinical-Stage, Off-The-Shelf CAR NK-Cell Therapy Platform – BioSpace

By Stem Cell Medical Center

Nov. 5, 2019 12:00 UTC

HOUSTON & OSAKA, Japan--(BUSINESS WIRE)-- The University of Texas MD Anderson Cancer Centerand Takeda Pharmaceutical Company Limited (TSE:4502/NYSE:TAK) (Takeda) today announced an exclusive license agreement and research agreement to develop cord blood-derived chimeric antigen receptor-directed natural killer (CAR NK)-cell therapies, armored with IL-15, for the treatment of B-cell malignancies and other cancers.

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20191105005250/en/

Under the agreement, Takeda will receive access to MD Andersons CAR NK platform and the exclusive rights to develop and commercialize up to four programs, including a CD19-targeted CAR NK-cell therapy and a B-cell maturation antigen (BCMA)-targeted CAR NK-cell therapy. Takeda and MD Anderson will also conduct a research collaboration to further develop these CAR NK programs.

Our vision is to improve upon existing treatments by developing armored CAR NKs that could be administered off-the-shelf in an outpatient settingenabling more patients to be treated effectively, quickly and with minimal toxicities, said Katy Rezvani, M.D., Ph.D., professor of Stem Cell Transplantation and Cellular Therapy at MD Anderson. With their expertise in hematologic malignancies and commitment to developing next-generation cell therapies, Takeda is the ideal collaborator to help our team advance CAR NK-cell therapies to patients in need of treatments.

A Novel Approach to Delivering Off-the-Shelf CARs in an Outpatient Setting MD Andersons allogeneic CAR NK platform isolates NK cells from umbilical cord blood and engineers them to express CARs against specified cancer targets. CAR NK cells are modified with a retroviral vector to deliver genes and enhance their effectiveness to attack specific tumors. A CD19 CAR increases the cells specificity for B-cell malignancies while the immunocytokine IL-15 enhances the proliferation and survival of the CAR NK cells in the body.

In contrast to current CAR T-cell therapies that utilize a patients own genetically modified T-cells and require a multi-week manufacturing process, CAR NK cells are intended to be manufactured from a non-related donor source and stored for off-the-shelf use, allowing treatment to be delivered more rapidly.

It is anticipated that the CD19 CAR NK-cell therapy could be administered in an outpatient setting. In an ongoing phase 1/2a clinical study treating patients with relapsed and refractory B-cell malignances, the CD19 CAR NK-cell therapy has not been associated with the severe cytokine release syndrome (CRS) or neurotoxicity observed with existing CAR-T therapies.

The development of MD Andersons CAR NK platform is led by Dr. Rezvani and is further supported by the adoptive cell therapy platform, Chronic Lymphocytic Leukemia Moon Shot and B-Cell Lymphoma Moon Shot, all part of the institutions Moon Shots Program, a collaborative effort to rapidly develop scientific discoveries into meaningful clinical advances that save patients lives.

Takeda: Accelerating the Development of Multiple Next-Generation CAR Platforms MD Andersons CAR NK platform represents the curative potential of cell therapies, which is why we are establishing the CD19 CAR NK as our lead cell therapy candidate in oncology, said Andy Plump, M.D., Ph.D., President of Research and Development at Takeda. We need to work swiftly and with purpose, and as such, we intend to initiate a pivotal study of the CD19 CAR NK in 2021.

In addition to CAR NK-cell therapies, Takeda and its partners are investigating multiple approaches to improving the safety, efficacy and accessibility of first-generation CAR T-cell therapies including gamma delta CAR Ts, induced pluripotent stem cell-derived CAR Ts, CAR Ts targeting solid tumors, and other next-generation approaches. Takeda plans to advance five oncology cell therapies to the clinic by the end of FY20.1 These platforms are being developed both with partners and by applying the expertise of Takedas translational cell therapy engine which provides bioengineering, chemistry, manufacturing and control (CMC), clinical and translational capabilities in a single footprint to overcome many of the manufacturing challenges experienced in cell therapy development.

Takeda is responsible for the development, manufacturing and commercialization of CAR NK products resulting under the agreement. MD Anderson will receive an upfront payment and is eligible to receive development and commercial milestones for each target as well as tiered royalties on net sales of any such CAR NK product.

MD Anderson and Takeda will continue research for the additional targets and CAR NK platform under the direction of a joint research committee. MD Anderson will implement an Institutional Conflict of Interest Management and Monitoring Plan for this research.

About MD Anderson The University of Texas MD Anderson Cancer Center in Houston ranks as one of the world's most respected centers focused on cancer patient care, research, education and prevention. The institutions sole mission is to end cancer for patients and their families around the world. MD Anderson is one of only 50 comprehensive cancer centers designated by the National Cancer Institute (NCI). MD Anderson is ranked No.1 for cancer care in U.S. News & World Reports Best Hospitals survey. It has ranked as one of the nations top two hospitals for cancer care since the survey began in 1990, and has ranked first 15 times in the last 18 years. MD Anderson receives a cancer center support grant from the NCI of the National Institutes of Health (P30 CA016672).

About Takeda Pharmaceutical Company Limited Takeda Pharmaceutical Company Limited (TSE:4502/NYSE:TAK) is a global, values-based, R&D-driven biopharmaceutical leader headquartered in Japan, committed to bringing Better Health and a Brighter Future to patients by translating science into highly-innovative medicines. Takeda focuses its R&D efforts on four therapeutic areas: Oncology, Gastroenterology (GI), Rare Diseases and Neuroscience. We also make targeted R&D investments in Plasma-Derived Therapies and Vaccines. We are focusing on developing highly innovative medicines that contribute to making a difference in people's lives by advancing the frontier of new treatment options and leveraging our enhanced collaborative R&D engine and capabilities to create a robust, modality-diverse pipeline. Our employees are committed to improving quality of life for patients and to working with our partners in health care in approximately 80 countries and regions. For more information, visit https://www.takeda.com

Forward-Looking Statements This press release and any materials distributed in connection with this press release may contain forward-looking statements, beliefs or opinions regarding Takedas future business, future position and results of operations, including estimates, forecasts, targets and plans for Takeda. In particular, this press release contains forecasts and management estimates related to the financial and operational performance of Takeda, including statements regarding forecasts for Revenue, Operating profit, Adjusted EBITDA, Profit before income taxes, Net profit attributable to owners of Takeda, Basic earnings per share, Amortization and impairment and other income/expense, Underlying Revenue, Underlying Core Earnings margin, Underlying Core EPS and Net Debt. Without limitation, forward looking statements often include the words such as targets, plans, believes, hopes, continues, expects, aims, intends, will, may, should, would, could anticipates, estimates, projects or words or terms of similar substance or the negative thereof. Any forward-looking statements in this document are based on the current assumptions and beliefs of Takeda in light of the information currently available to it. Such forward-looking statements do not represent any guarantee by Takeda or its management of future performance and involve known and unknown risks, uncertainties and other factors, including but not limited to: the economic circumstances surrounding Takedas business, including general economic conditions in Japan, the United States and worldwide; competitive pressures and developments; applicable laws and regulations; the success of or failure of product development programs; decisions of regulatory authorities and the timing thereof; changes in exchange rates; claims or concerns regarding the safety or efficacy of marketed products or products candidates; and post-merger integration with acquired companies, any of which may cause Takedas actual results, performance, achievements or financial position to be materially different from any future results, performance, achievements or financial position expressed or implied by such forward-looking statements. For more information on these and other factors which may affect Takedas results, performance, achievements, or financial position, see Item 3. Key InformationD. Risk Factors in Takedas Registration Statement on Form 20-F filed with the U.S. Securities and Exchange Commission, available on Takedas website at: https://www.takeda.com/investors/reports/sec-filings/ or at http://www.sec.gov. Neither Takeda nor its management gives any assurances that the expectations expressed in these forward-looking statements will turn out to be correct, and actual results, performance or achievements could materially differ from expectations. Persons receiving this press release should not place undue reliance on forward looking statements. Takeda undertakes no obligation to update any of the forward-looking statements contained in this press release or any other forward-looking statements it may make. Past performance is not an indicator of future results and the results of Takeda in this press release may not be indicative of, and are not an estimate, forecast or projection of Takedas future results.

1 Takedas 2020 fiscal year begins April 1, 2020 and ends March 31, 2021.

View source version on businesswire.com: https://www.businesswire.com/news/home/20191105005250/en/

Link:
Takeda and MD Anderson Announce Collaboration to Accelerate the Development of Clinical-Stage, Off-The-Shelf CAR NK-Cell Therapy Platform - BioSpace

Stem Cell Therapy Market by Treatment,Application,End Users and Geography Forecast To 2026 – Markets Gazette 24

By Embryonic Stem Cells

Stem Cell Therapy Market is expected to reach 202.77 billion by 2026 from 12.25 billion in 2017 at CAGR of 42.02%.(Detailed analysis of the market CAGR is provided in the report) stands for use of stem cells to treat or prevent disease or condition.

Bone marrow transplant and some therapies derived from umbilical cord blood are mainly used in stem cell therapy. Advancement, in order to establish new sources for stem cells, and to apply stem-cell treatments for neurodegenerative diseases and conditions such as diabetes, heart disease, and other conditions, are increased in recent years. Stem Cell Therapy Market Researchers are making efforts to discover novel methods to create human stem cells. This will increase the demand as well as supply for stem cell production and potential investigation in disease management. Increasing investment & research grants for developing safe and effective stem cell therapy products, the growing patient base for target diseases, concentrated product pipelines, increasing approval of the new clinical trials, rapid technological advancement in genomics, and the rising awareness about the stem cell are expected to drive the growth of the Stem Cell Therapy solutions market during the forecast period.

REQUEST FOR FREE SAMPLE REPORT: https://www.maximizemarketresearch.com/request-sample/522

However, improper infrastructure, insufficient storage systems, nascent technology in underdeveloped economies, Ethical issues related to an embryonic stem cell, low patient acceptance rate, Difficulty in the preservation of stem cell are expected to restrain the market growth. North America is expected to be the largest growing region by 2026; the reason behind that is extensive funding by Government. However, Emerging countries like India, china, Korea have low growth rate as compared to Developed regions in 2017 but increase in awareness about stem cell therapy will lead the Asia Pacific to generate a significant level of revenue by 2026.

Key Highlights of Stem Cell Therapy Market report

Detailed quantitative analysis of the current and future trends from 2017 to 2026, which helps to identify the prevailing market opportunities.Comprehensive analysis of factors instrumental in changing the market scenario, rising prospective opportunities, market shares, core competencies in terms of market development, growth strategies and identification of key companies that can influence this market on a global and regional scale.Assessment of Market definition along with the identification of key drivers, restraints opportunities and challenges for this market during the forecast period.Complete analysis of micro-markets with respect to individual growth trends, prospects, and contributions to the overall Stem Cell Therapy Solutions market.Stem Cell Therapy market analysis and comprehensive segmentation with respect to the Application, End users, Treatment, and geography to assist in strategic business planning.Stem Cell Therapy market analysis and forecast for five major geographies-North America, Europe, Asia Pacific, Middle East & Africa, Latin America, and their key regions.For company profiles, 2017 has been considered as the base year. In cases, wherein information was unavailable for the base year, the years prior to it have been considered.

Research Methodology:

The market is estimated by triangulation of data points obtained from various sources and feeding them into a simulation model created individually for each market. The data points are obtained from paid and unpaid sources along with paid primary interviews with key opinion leaders (KOLs) in the market. KOLs from both, demand and supply side were considered while conducting interviews to get an unbiased idea of the market. This exercise was done at a country level to get a fair idea of the market in countries considered for this study. Later this country-specific data was accumulated to come up with regional numbers and then arrive at a global market value for the stem cell therapy market.

Key Players in the Stem Cell Therapy Market are:

Chiesi Farmaceutici S.P.A Are:Gamida CellReNeuron Group, plcOsiris Therapeutics, Inc.Stem Cells, Inc.Vericel Corporation.Mesoblast, Ltd.

Key Target Audience:

Stem Cell Associations and OrganizationsGovernment Research Boards and OrganizationsResearch and consulting firmsStem Cell Therapy Market InvestorsHealthcare Service Providers (including Hospitals and Diagnostic Centers)Stem Cell Therapeutic Product Manufacturing OrganizationsResearch LabsClinical research organizations (CROs)Stem Cell Therapy Marketing PlayersPharmaceutical Product Manufacturing Companies

DO INQUIRY BEFORE PURCHASING REPORT HERE: https://www.maximizemarketresearch.com/inquiry-before-buying/522

Scope of the Stem Cell Therapy Market Report:

Stem Cell Therapy market research report categorizes the Stem Cell Therapy market based on Application, End users, Treatment, and geography (region wise). Market size by value is estimated and forecasted with the revenues of leading companies operating in the Stem Cell Therapy market with key developments in companies and market trends.

Stem Cell Therapy Market, By Treatments:

Allogeneic Stem Cell TherapyAutologous Stem Cell Therapy

Stem Cell Therapy Market, By End Users:

HospitalsAmbulatory Surgical Centers

Stem Cell Therapy Market, By Application:

OncologyCentral Nervous System DiseasesEye DiseasesMusculoskeletal DiseasesWound & InjuriesMetabolic DisordersCardiovascular DisordersImmune System Disorders

Stem Cell Therapy Market, By Geography:

North AmericaEuropeAsia PacificMiddle East & AfricaLatin America

Available Customization:

With the given market data, Maximize Market Research offers customization of report and scope of the report as per the requirement

Regional Analysis:

Breakdown of the North America stem cell therapy marketBreakdown of the Europe stem cell therapy marketBreakdown of the Asia Pacific stem cell therapy marketBreakdown of the Middle East & Africa stem cell therapy marketBreakdown of the Latin America stem cell therapy market

Company Information:Detailed analysis and profiles of addition

Browse Full Report with Facts and Figures of Stem Cell Therapy Market Report at: https://www.maximizemarketresearch.com/market-report/stem-cell-therapy-market/522/

MAJOR TOC OF THE REPORT

Chapter One: Stem Cell Therapy Market Overview

Chapter Two: Manufacturers Profiles

Chapter Three: Global Stem Cell Therapy Market Competition, by Players

Chapter Four: Global Stem Cell Therapy Market Size by Regions

Chapter Five: North America Stem Cell Therapy Revenue by Countries

Chapter Six: Europe Stem Cell Therapy Revenue by Countries

Chapter Seven: Asia-Pacific Stem Cell Therapy Revenue by Countries

Chapter Eight: South America Stem Cell Therapy Revenue by Countries

Chapter Nine: Middle East and Africa Revenue Stem Cell Therapy by Countries

Chapter Ten: Global Stem Cell Therapy Market Segment by Type

Chapter Eleven: Global Stem Cell Therapy Market Segment by Application

Chapter Twelve: Global Stem Cell Therapy Market Size Forecast (2019-2026)

About Us:

Maximize Market Research provides B2B and B2C market research on 20,000 high growth emerging technologies & opportunities in Chemical, Healthcare, Pharmaceuticals, Electronics & Communications, Internet of Things, Food and Beverages, Aerospace and Defense and other manufacturing sectors.

Contact info:

Name: Lumawant Godage

Organization: MAXIMIZE MARKET RESEARCH PVT. LTD.

Email: sales@maximizemarketresearch.com

Contact: +919607065656/ +919607195908

Website: http://www.maximizemarketresearch.com

The rest is here:
Stem Cell Therapy Market by Treatment,Application,End Users and Geography Forecast To 2026 - Markets Gazette 24

Global Stem Cell Assay Market 2019 Size, Share, Growth, Trends, Type, Application, Analysis and Forecast by 2026 – Markets Gazette 24

By Embryonic Stem Cells

The investment made in the study would provide you access to the information such as:

Request for a sample of this research report @ https://www.orianresearch.com/request-sample/1353714

Highlights of the report:A complete backdrop analysis, which includes an assessment of the parent market. Important changes in market dynamics market segmentation up to the second or third level. Historical, current, and projected size of the market from the standpoint of both value and volume. Reporting and evaluation of recent industry developments market shares and strategies of key players. Emerging niche segments and regional markets. Objective assessment of the trajectory of the market. Recommendations to companies for strengthening their foothold in the market

On the basis of type, the market is split into:* Viability/Cytotoxicity* Isolation & Purification* Cell Identification* Proliferation* Differentiation* Function* Apoptosis

On the basis of cell type, the market is split into:* Human embryonic stem cells (hESCs)* Adult Stem Cells

On the basis of product & service, the market is split into:* Instruments* Kits* Services

The key players profiled in the market include:* Thermo Fisher Scientific* Merck KGaA* GE Healthcare* Bio-Rad Laboratories* Promega Corporation* Agilent Technologies* Perkinelmer

Buy one-Get one: https://www.orianresearch.com/checkout/1353714

Buy this report and get another report of the same price for free! Offer for limited period only!!!

Key Benefits of the Report:

* Global, regional, type, cell type, product & service, application, end user market size and their forecast from 2015-2026

* Identification and detailed analysis on key market dynamics, such as, drivers, restraints, opportunities, and challenges influencing growth of the market

* Detailed analysis on industry outlook with market specific PESTLE, and supply chain to better understand the market and build expansion strategies

* Identification of key market players and comprehensively analyze their market share and core competencies, detailed financial positions, key products, and unique selling points

* Analysis on key players strategic initiatives and competitive developments, such as joint ventures, mergers, and new product launches in the market

* Expert interviews and their insights on market shift, current and future outlook, and factors impacting vendors short term and long term strategies

* Detailed insights on emerging regions, type, cell type, product & service, application, end user with qualitative and quantitative information and facts

Target Audience:

* Stem Cell Assay Product Manufacturers

* Traders, Importers, and Exporters

* Raw Material Suppliers and Distributors

* Government and Research Organizations

* Associations and Industry Bodies

GET Flat 40% Discount: https://www.orianresearch.com/discount/1353714

Limited period discount offer!!! Purchase reports before the offer ends!!!

Research Methodology:

The market is derived through extensive use of secondary, primary, in-house research followed by expert validation and third party perspective, such as, analyst reports of investment banks. The secondary research is the primary base of our study wherein we conducted extensive data mining, referring to verified data sources, such as, white papers, government and regulatory published articles, technical journals, trade magazines, and paid data sources.

For forecasting, regional demand & supply factors, recent investments, market dynamics including technical growth scenario, consumer behavior, and end use trends and dynamics, and production capacity were taken into consideration. Different weightages have been assigned to these parameters and quantified their market impacts using the weighted average analysis to derive the market growth rate.

The market estimates and forecasts have been verified through exhaustive primary research with the Key Industry Participants (KIPs), which typically include:

* Manufacturers

* Suppliers

* Distributors

* Government Body & Associations

* Research Institutes

See original here:
Global Stem Cell Assay Market 2019 Size, Share, Growth, Trends, Type, Application, Analysis and Forecast by 2026 - Markets Gazette 24

Global Progenitor Cell-Based Market to Witness Robust Expansion throughout the Forecast 2026 – Herald Correspondent

By Stem Cell Medicine

Global Progenitor Cell-Based Market By Type (Allogeneic Stem Cell, Autologous Stem Cell), Therapeutic Application (Musculoskeletal Disorders, Wound and Injuries, Neurology, Cardiovascular Diseases (CVD), Gastrointestinal Diseases, Surgeries, Others), Cell Source (Adipose Tissue-Derived Mesenchymal Stem Cells, Bone Marrow-Derived Mesenchymal Stem Cells, Embryo/Cord Blood Stem Cells, Others), End User (Laboratory, Hospitals, Research Institute), Geography (North America, Europe, Asia-Pacific, South America, Middle East and Africa) Industry Trends and Forecast to 2026

Global progenitor cell-based market is estimated to register a substantial CAGR in the forecast period of 2019 to 2026. The imminent market report contains data for historic year 2017, the base year of calculation is 2018 and the forecast period is 2019 to 2026. The growth of the market can be attributed to the rising geriatric population.

Progenitor cell are the kind of stem cell which are located in bone marrow and also called as hematopoietic. These cells give rise to the different cell lines. The progenitor cells can divide and stem cells can replicate indefinitely. Progenitor cells are used in various neurological disorders such as Parkinson disease and Huntington disease.

Prevalence of Parkinsons disease (PD) increases with increasing age but an estimated four percent of people with Parkinsons disease are diagnosed before age 50, more than 10 million people worldwide are living with Parkinsons disease, and other neurological diseases.

Market Drivers

Market Restraints

Get Sample Analysis of Global Market Information: https://www.databridgemarketresearch.com/request-a-sample/?dbmr=global-progenitor-cell-based-market

By Type

By Therapeutic Application

By Cell Source

By End User

By Geography

Get TOC of Full Report: https://www.databridgemarketresearch.com/toc/?dbmr=global-progenitor-cell-based-market

Key Developments in the Market:

Competitive Analysis:

Global progenitor cell-based market is highly fragmented and the major players have used various strategies such as new product launches, expansions, agreements, joint ventures, partnerships, acquisitions, and others to increase their footprints in this market. The report includes market shares of progenitor cell-based market for Global, Europe, North America, Asia-Pacific, South America and Middle East & Africa.

Key Market Competitors:

Some of the major companies functioning in global progenitor cell-based market are F. Hoffmann-La Roche Ltd, Pfizer Inc., Merck & Co., Inc., Abbott, Vericel, Novartis AG, Alcon, GlaxoSmithKline plc, BAXTER INTERNATIONAL INC, Boehringer Ingelheim International GmbH, Amgen Inc., Bristol-Myers Squibb Company, Nuvasive, Inc., Organogenesis, Inc., Nu-Tech International, MiMedx, Stability Biologic., Takara Bio Inc., Caladrius, Biosciences, Inc., U.S. Stem Cell, Inc., Cesca Therapeutics and Osiris Therapeutics, Inc among others

Data assemblage and base year analysis is done using data collection modules with large sample sizes. The market data is analysed and forecasted using market statistical and coherent models. Also market share analysis and key trend analysis are the major success factors in the market report. To know more pleaserequest an analyst callor can drop down your enquiry.

The key research methodology used byDBMR researchteam is data triangulation which involves data mining, analysis of the impact of data variables on the market, and primary (industry expert) validation. Apart from this, other data models include Vendor Positioning Grid, Market Time Line Analysis, Market Overview and Guide, Company Positioning Grid, Company Market Share Analysis, Standards of Measurement, Top to Bottom Analysis and Vendor Share Analysis. To know more about the research methodology, drop in an inquiry to speak to our industry experts.

Primary Respondents

Demand Side: Doctors, Surgeons, Medical Consultants, Nurses, Hospital Buyers, Group Purchasing Organizations, Associations, Insurers, Medical Payers, Healthcare Authorities, Universities, Technical Writers, Scientists, Promoters, and Investors among others.

Reasons to Purchase this Report

Customization of the Report:

To Know More :https://www.databridgemarketresearch.com/reports/global-progenitor-cell-based-market

About Us

Data Bridge Market Researchis a versatile market research and consulting firm with over 500 analysts working in different industries. We have catered more than 40% of the fortune 500 companies globally and have a network of more than 5000+ clientele around the globe. Our coverage of industries include Medical Devices, Pharmaceuticals, Biotechnology, Semiconductors, Machinery, Information and Communication Technology, Automobiles and Automotive, Chemical and Material, Packaging, Food and Beverages, Cosmetics, Specialty Chemicals, Fast Moving Consumer Goods, Robotics, among many others.

Data Bridge adepts in creating satisfied clients who reckon upon our services and rely on our hard work with certitude. GetCustomizationandDiscounton Report by emailingCorporatesales@databridgemarketresearch.com. We are content with our glorious 99.9 % client satisfying rate.

Contact Us

Data Bridge Market Research

US: +1 888 387 2818

UK: +44 208 089 1725

Hong Kong: +852 8192 7475Mail:Corporatesales@databridgemarketresearch.comhttps://databridgemarketresearch.com

Read the original here:
Global Progenitor Cell-Based Market to Witness Robust Expansion throughout the Forecast 2026 - Herald Correspondent

Business Analytics of Regenerative Medicine Market to See Excellent Growth by 2026 |Popular Keysights: Organogenesis Inc., Vericel Corporation, Osiris…

By Stem Cell Medicine

The Regenerative Medicine Market is anticipated to reach over USD 79.23 billion by 2026 according to a new research published by Alexa Reports Research. In 2017, the cell therapy dominated the global Regenerative Medicine market, in terms of revenue. North America is expected to be the leading contributor to the global market revenue in 2017.

Regenerative medicine is a branch of medicine that regrows, and repairs the damaged cells in the human body. These medicines include the use of stem cells, tissue engineering, that further helps in developing new organ that function smoothly. These medicines have the caliber of developing an entire organ as these cells are multipotent. The cells are majorly isolated from bone marrow, and umbilical cord blood.

Get Sample Report PDF of Regenerative Medicine research report @ https://www.alexareports.com/report-sample/10264

The regenerative medicine market is primarily driven by the increasing number of individuals suffering from cancer, rising need to monitor and treating these chronic diseases in the limited time. Furthermore, stringent government policies, proper reimbursement policies, and increasing government healthcare expenditure for developing healthcare infrastructure to also boost the market growth in coming years. Also, rising number of organ transplantation, and increasing number of products in pipeline that are waiting for approval create major opportunity for the regenerative medicines in the coming years. However, some of the ethical and religious concerns for the use of stem cells, and lack of proper regulatory for the approval of various drugs would impede the market growth during the forecast period.

North America generated the highest revenue in the Regenerative Medicine market in 2017, and is expected to be the leading region globally during the forecast period. Increasing number of patients suffering from chronic diseases, improved healthcare infrastructure and health facilities, accessibility of healthcare facilities, are the primary factors driving the market growth in this region. While, Asia Pacific to be the fastest growing region in the coming years. The growth in this region is majorly attributed to the developing healthcare infrastructure of the countries like India, & China, and rising awareness for the use of regenerative medicines as an effective treatment option for chronic diseases.

The key players operating in the Regenerative Medicine market include Organogenesis Inc., Vericel Corporation, Osiris Therapeutics, Inc., Stryker Corporation, and NuVasive, Inc., Medtronic Plc., Acelity, Cook Biotech Inc., Integra LifeSciences, and C.R. Bard. These companies launch new products and collaborate with other market leaders to innovate and launch new products to meet the increasing needs and requirements of consumers.For Getting [emailprotected] https://www.alexareports.com/check-discount/10264

About Us:Alexa Reports is a globally celebrated premium market research service provider, with a strong legacy of empowering business with years of experience. We help our clients by implementing decision support system through progressive statistical surveying, in-depth market analysis, and reliable forecast data.

Contact Us:Alexa ReportsPh no: +1-408-844-4624 / +91- 7030626939Email: [emailprotected]Site: https://www.alexareports.com

Go here to see the original:
Business Analytics of Regenerative Medicine Market to See Excellent Growth by 2026 |Popular Keysights: Organogenesis Inc., Vericel Corporation, Osiris...

Stem Cell Transplants Used to Grow Fully Functional Lungs in Mice – Technology Networks

By Stell Cell Research

Researchers at Columbia University were able to grow fully functional lungs in mouse embryos using transplanted stem cells. The findings suggest that it may be ultimately possible to use the technique to grow human lungs in animals for patients who need transplants and to study new lung treatments.

Millions of people worldwide who suffer from incurable lung diseases die without treatment due to the limited supply of donor lungs for transplantation, said co-senior author Wellington V. Cardoso, MD, PhD, professor of medicine and of genetics & development at Columbia University Vagelos College of Physicians and Surgeons. Our study shows that it may eventually be possible to develop new strategies for generating human lungs in animals for transplantation as an alternative to waiting for donor lungs.

Researchers have dedicated major efforts to bioengineer lungs by growing stem cells on synthetic scaffolds or in lungs that have been stripped of their original cells. Though substantial progress has been made, researchers have been unable to generate a fully functional lung capable of maintaining survival in animal models.

We thought it might be simpler to grow new lungs in a developing animal, so that we could take advantage of the animals natural signals for lung development, says first author Munemasa Mori, MD, PhD, instructor of medicine at Columbia University Vagelos College of Physicians and Surgeons.

The researchers first challenge was to create tissue culture conditions that would allow the donor stem cells to expand proliferate and maintain their ability to transform into many different cell types.

Next, the researchers implanted these stem cells in two types of engineered mouse embryos. One type lacked the stem cells that develop into mature lung cells and another could not produce enough of the cells to make a lung. This procedure created a chimeric embryo that was a mix of donor and host cells.

The implanted stem cells outcompeted the host cells for growth-promoting molecules present in the embryo, leading to the formation of functional lungs that allowed the mice to live well into adulthood. A variety of lung function tests confirmed that the chimeric lungs worked as well as normal mouse lungs, with no signs of rejection.

The stem cells were implanted before the embryos immunological system was turned on, which may explain why the organs were not rejected, says Mori, who will later test his approach in larger animals and in interspecies organ transplants.

Many of the signals for lung development are conserved across species, from frogs to mice to humans, so the idea of using animals to grow human lungs is not out of the question, Cardoso says.

The research was performed in collaboration with Hiromitsu Nakauchi, PhD, a professor at Stanford University School of Medicine and the University of Tokyo, a co-senior author of the paper.

Reference:Mori, M., Furuhashi, K., Danielsson, J. A., Hirata, Y., Kakiuchi, M., Lin, C.-S., Cardoso, W. V. (2019). Generation of functional lungs via conditional blastocyst complementation using pluripotent stem cells. Nature Medicine. https://doi.org/10.1038/s41591-019-0635-8

This article has been republished from the following materials. Note: material may have been edited for length and content. For further information, please contact the cited source.

Read more:
Stem Cell Transplants Used to Grow Fully Functional Lungs in Mice - Technology Networks

→←